COVID-19Phase 1NCT05548439
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
A Phase 1 study testing VBI-2901a in people with COVID-19 and Coronavirus Infections, run by VBI Vaccines Inc. at 7 sites in Canada.
Trial summary
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and MERS-CoV. Read more about this study
- Who is it for?
- Ages 18 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- COVID-19, Coronavirus Infections
- What is being tested?
- VBI-2901a
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 103 participants
- Where
- 7 sitesCanada
- Study dates
- 5 Oct 2022to 16 Jan 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male or female subject 18-64 years of age
- Be willing and able to provide personally signed informed consent indicating understanding of the purpose, procedures required for the study and potential risks and benefits of the study, and be willing to participate in the study
- Be healthy or in stable health. Participants with pre-existing, stable, well-controlled disease, defined as mild disease or medical condition not requiring medical therapy or not requiring a change in medical therapy due to worsening of disease during the 6 months before enrollment may be enrolled at the discretion of the investigator. Participants with history of asymptomatic SARS-CoV-2 infection who tested positive by PCR or rapid antigen test or participants with history of having signs and symptoms mild COVID-19 illness (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who did not have shortness of breath, dyspnea, or abnormal chest imaging are eligible for the study if they fully recovered a minimum of 6 months before enrollment.
- Meets reproductive inclusion criteria
- Female participants
- Female participant is eligible if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
Show all 15Show fewer
- is of childbearing potential and must have a negative pregnancy test prior to study vaccinations and agree to use an effective method of birth control as deemed appropriate by the investigator (e.g., hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) beginning >30 days prior to the first study vaccine administration and continuing for a minimum of 30 days after the last dose of study vaccine.
- OR
- is not of childbearing potential, defined as postmenopausal (a minimum of 12 months with no menses without an alternative medical cause) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).
- Male participants
- Male participant is eligible to participate if he agrees to the following requirements from the time of first study vaccination until at least 30 days after the last dose of study vaccine:
- Be abstinent from heterosexual intercourse with a female of childbearing potential OR
- Must agree to use a male condom. In addition to male condom use, an effective method of contraception may be considered in female partners of male participants AND
- Must refrain from sperm donation
- Have previously received 2 or more doses of a licensed COVID-19 vaccine(s) with the last dose administered a minimum of 6 months (24 weeks) prior to enrollment. Participants vaccinated with any of the vaccines approved by Health Canada for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) in individuals 18 years of age and older are eligible for the study. This includes the following COVID-19 vaccines: Moderna Spikevax®, Pfizer-BioNTech Comirnaty®, AstraZeneca Vaxzevria®, Janssen Jcovden® (Johnson \& Johnson), Novavax Nuvaxovid® and Medicago Covifenz®. Participants who received one or more doses of VBI-2902a, VBI-2905a or any other COVID-19 vaccines that are either investigational or not approved by Health Canada are not eligible for the study.
Who cannot join
- History of COVID-19 illness of moderate or greater severity, defined as one of the following:
- Moderate Illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥94% on room air at sea level.
- Severe COVID-19 illness: Individuals who have SpO2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, a respiratory rate >30 breaths/min, or lung infiltrates >50%.
- Critical COVID-19 illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.
- Participants with a known history of SARS-CoV-1 or MERS infection.
- Positive SARS-CoV-2 PCR or rapid antigen test at screening.
Show all 26Show fewer
- Participant with a history of an underlying clinically significant acute or chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation in the study would not be in the best interest of the participant (e.g., could compromise participant's wellbeing) or that could prevent, limit, or confound the protocol-specified assessments.
- Individuals with medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- History of cancer requiring chemotherapy or radiation within 5 years
- Lack of participant's capacity (mental, social, behavioral), in the investigator's judgement, to provide informed consent for participation in the study.
- Known or suspected impairment of immunological function, including but not limited to autoimmune diseases:
- autoimmune diseases (e.g. multiple sclerosis, type 1 diabetes, myasthenia gravis, Crohn's disease and other inflammatory bowel diseases, celiac disease, systemic lupus erythematosus, scleroderma, including diffuse systemic form and CREST syndrome, systemic sclerosis, dermatomyositis polymyositis, rheumatoid arthritis, juvenile idiopathic arthritis, autoimmune thyroiditis - including Hashimoto thyroiditis, Grave's or Basedow's disease, immune thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune hepatitis, psoriasis, vitiligo, vasculitis, Guillain- Barré syndrome, transverse myelitis, Addison's disease, Bell's palsy and alopecia areata);
- secondary immunodeficiency disorders (e.g., Acquired Immunodeficiency Syndrome caused by Human Immunodeficiency Virus infection (HIV/AIDS), solid organ transplant, splenectomy);
- primary immunodeficiency disorders (e.g., common variable immune deficiency (CVID), defective phagocytic cell function and neutropenia syndromes, complement deficiency).
- History of allergic reactions or anaphylactic reaction to any vaccine component.
- Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV). Negative result of Anti-HIV, Anti-HCV and HBsAg testing at screening is required for eligibility.
- Pregnant or breastfeeding or plans to conceive from 2 weeks before the study until the end of study.
- Clinically significant abnormal physical examination, vital signs, or clinically significant abnormal values for hematology, serum chemistry or urinalysis at screening as determined by the investigator.
- Any laboratory test abnormality that would be considered of Grade 1 severity or above (as per FDA grading guidelines) and is considered as clinically significant by the investigator. Grade 2 severity or above is exclusionary, regardless of clinical assessment.
- Receipt of blood products or immunoglobulin within 90 days prior to enrollment or likely to require blood products during the study period.
- Chronic administration (defined as more than 14 days in total) of immune-suppressive or other immune-modifying drug within 6 months prior to enrollment (for corticosteroids, this is defined as prednisone ≥20 mg/day or equivalent). Inhaled and topical steroids are allowed.
- Immunization with attenuated vaccines (e.g., shingles) within 4 weeks prior to enrollment.
- Immunization with inactivated vaccines (e.g., influenza) within 2 weeks prior to enrollment.
- Participation in another clinical study within 30 days prior to enrollment. Participants who received one or more doses of VBI-2902a or VBI-2905a or other investigational COVID-19 vaccines are not eligible for the study.
- Any skin abnormality or tattoo that would limit post-vaccination injection site assessment.
- Family members of study site personnel.
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
Canada7 sites
Canadian Center for Vaccinology
Halifax, Nova Scotia, B3K 6R8
Red Maple Trials
Ottawa, Ontario, K1H 1E4
Ottawa Hospital
Ottawa, Ontario, K1H 8L6
Manna Research Inc
Pointe-Claire, Quebec, H9R 4S3
CHU de Québec Université Laval
Québec, Quebec, G1E 7G9
LMC Manna - Bayview CPU
Toronto, Ontario, M4G 3E8
LMC Manna Toronto
Toronto, Ontario, M9W 4L6
About this study
Official title: A Phase 1, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901a, a Trivalent Coronavirus Vaccine Candidate in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and MERS-CoV. The trivalent vaccine candidate is designed to induce neutralizing antibody and cell-mediated immune responses against the spike protein of the original strain of SARS-CoV-2, SARS-CoV-2 variants (such as Beta, Delta and Omicron) and other related coronaviruses that could emerge in the future.
The Phase 1 study will be an open-label comparison of two intramuscular doses of VBI-2901a at 5 µg or 10 µg per dose or one dose of VBI-2901a at 10 µg per dose in adults 18 to 64 years of age who had previously received two or more vaccinations with licensed COVID-19 vaccines. The purpose of the study is to test the safety of VBI-2901a and to know more about its ability to boost immune response against SARS-CoV-2 (the virus that causes COVID-19 disease) and two other related coronaviruses SARS-CoV-1 and MERS-CoV.
Read the detailed description
VBI-2901a is an investigational trivalent COVID-19 vaccine candidate that comprises enveloped virus-like particles (eVLPs) expressing the spike proteins of the beta-coronaviruses SARS-CoV-2, SARS-CoV-1 and MERS-CoV. The study will enroll participants 18 to 64 years of age who have previously received two or more vaccinations with a licensed COVID-19 vaccine(s) and will test two intramuscular doses of VBI-2901a containing 5 µg or 10 µg of spike protein and one dose of VBI-2901a containing 10 µg of spike protein. VBI-2901a eVLPs are formulated with 0.33 mg of aluminum phosphate (alum) adjuvant per dose. VBI-2901a is designed to induce neutralizing antibody and cell-mediated immune responses against multiple coronavirus respiratory disease strains and variants of SARS-CoV-2.
This is a randomized, open-label Phase 1 study. The study will enroll adults, aged 18 to 64 years, who are healthy or in stable health; had previously received two or more vaccinations with a licensed COVID-19 vaccine(s) with the final dose administered a minimum of 6 months (24 weeks) prior to enrollment; have a negative PCR or rapid antigen SARS-CoV-2 test at screening; and have met all other eligibility criteria. Participants with a history of mild COVID-19 illness are eligible if they fully recovered a minimum of 6 months (24 weeks) prior to enrollment.
A total of 99 participants will be randomized at a 1:1:1 ratio to the following study groups:
Group G1: 33 participants to receive two doses of VBI-2901a at 5 µg per dose at Day 1 and Day 56.
Group G2: 33 participants to receive two doses of VBI-2901a at 10 µg per dose at Day 1 and Day 56.
Group G3: 33 participants to receive one dose of VBI-2901a at 10 µg per dose at Day 1.
The total study duration for each vaccinated subject is 48 weeks (336 days) after administration of the first dose of study vaccine. During the study, the participant will make 9 visits to the study site, including the screening visit.
The objective of the study is to select the optimal dose level (5 µg or 10 µg) and number of doses (1 or 2 doses) of trivalent coronavirus vaccine candidate VBI-2901a in individuals who had been vaccinated against COVID-19 previously. To achieve this objective, the study will evaluate outcomes including safety and tolerability as well as antibody and T cell immune responses against SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants, SARS-CoV-1 and MERS-CoV.
- Conditions
- COVID-19, Coronavirus Infections
- Being tested
- VBI-2901a
- Keywords
- COVID-19, SARS-CoV-2, SARS-CoV-1, MERS-CoV, vaccine, enveloped virus-like particle (eVLP), coronavirus
- Medical subject headings
- COVID-19, Coronavirus Infections, Severe Acute Respiratory Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VBI-2901aBiological
Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
| Study group | Role | What they receive |
|---|---|---|
| Group G1 | Experimental | 33 participants aged 18-64 years to receive two doses of VBI-2901a at 5 µg per dose at Day 1 and Day 56. Receives: Biological: VBI-2901a |
| Group G2 | Experimental | 33 participants aged 18-64 years to receive two doses of VBI-2901a at 10 µg per dose at Day 1 and Day 56. Receives: Biological: VBI-2901a |
| Group G3 | Experimental | 33 participants aged 18-64 years to receive one dose of VBI-2901a at 10 µg per dose at Day 1. Receives: Biological: VBI-2901a |
What is being measured
The primary outcome is the main question the study is designed to answer.
Local reactions (solicited adverse events) within 7 days of study vaccination
Measured: Through 7 days after each vaccination
Systemic reactions (solicited adverse events) within 7 days of study vaccination
Measured: Through 7 days after each vaccination
Unsolicited adverse events within 28 days of study vaccination
Measured: Through 28 days after each vaccination
Serious adverse events within 28 days of study vaccination and end of study
Measured: Through end of study (approximately 1 year)
Medically-attended adverse events within 28 days of study vaccination and end of study
Measured: Through end of study (approximately 1 year)
Seroresponse rate against SARS-CoV-2 ancestral (Wuhan) strain
Percent of participants with ≥ 4-fold rise in neutralizing antibody titer at 28 days after the first vaccination and, in participants receiving two doses, 28 days after the second vaccination, compared to baseline (Day 1).
Measured: Study days 1, 28 and 84
Secondary outcomes (7)
Seroresponse rate against SARS-CoV-2 variants of concern (Beta, Delta and Omicron)
Percent of participants with ≥ 4-fold rise in neutralizing antibody titer at 28 days after the first vaccination and, in participants receiving two doses, 28 days after the second vaccination, compared to baseline (Day 1).
Measured: Study days 1, 28 and 84
Seroresponse rate against SARS-CoV-1 and MERS-CoV
Percent of participants with ≥ 4-fold rise in neutralizing antibody titer at 28 days after the first vaccination and, in participants receiving two doses, 28 days after the second vaccination, compared to baseline (Day 1).
Measured: Study days 1, 28 and 84
Geometric mean titer (GMT) of SARS-CoV-2 neutralizing antibodies
Geometric mean titer of SARS-CoV-2 neutralizing antibodies against SARS-CoV-2 ancestral (Wuhan) strain and variants of concern (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV at days 1, 7, 28, 56, 63, 84, 168 and 336.
Measured: Study days 1, 7, 28, 56, 63, 84, 168 and 336
Geometric mean fold rise (GMFR) in serum neutralizing antibody titer against SARS-CoV-2 ancestral (Wuhan) strain and variants of concern (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV
Geometric mean fold rise in serum neutralizing antibody titer against SARS-CoV-2 ancestral (Wuhan) strain and variants of concern (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV at Days 7, 28, 56, 63, 84, 168 and 336 compared to baseline (Day 1).
Measured: Study days 1, 7, 28, 56, 63, 84, 168 and 336
GMT and GMFR in serum IgG antibody to spike protein and receptor-binding-domain (RBD) against SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV
GMT and GMFR in serum IgG antibody to spike protein and receptor-binding-domain (RBD) by enzyme-linked immunosorbent assay (ELISA) against SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV at Days 7, 28, 56, 63, 84, 168, and 336 compared to baseline (Day 1)
Measured: Study days 1, 7, 28, 56, 63, 84, 168, and 336
Interferon-gamma-positive cells against spike protein from SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV
Geometric mean number of interferon-gamma-positive cells per million peripheral blood mononuclear cells (PBMCs) by ELISPOT using spike protein from SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV at Days 1, 7, 28, 56, 63, and 84
Measured: Study days 1, 7, 28, 56, 63, and 84
Serum binding IgG subclasses
Serum binding IgG subclasses as a marker of Th1 (IgG1 and IgG3) and Th2 (IgG4) dominated responses at Days 1, 7, 28, 56, 63, and 84
Measured: Days 1, 7, 28, 56, 63, and 84
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2022
- Study start5 Oct 2022
- Primary completion16 Jan 2024
- Study completion16 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 103 participants (actual)
Sponsor and investigators
- Lead sponsor
- VBI Vaccines Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- William Cameron, MD, Principal investigator, Ottawa Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05548439
- Sponsor's protocol ID
- VBI-2901a-CT01
- Status last verified
- May 2026
- First submitted
- 16 Sep 2022
- Last updated
- 11 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901a, a Trivalent Coronavirus Vaccine Candidate in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines
- ClinicalTrials.gov ID
- NCT05548439
- Acronym / sponsor ID
- VBI-2901a-CT01
- Conditions
- COVID-19, Coronavirus Infections
- Keywords
- COVID-19, SARS-CoV-2, SARS-CoV-1, MERS-CoV, vaccine, enveloped virus-like particle (eVLP), coronavirus
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 103 participants (actual)
- Lead sponsor
- VBI Vaccines Inc.Industry (pharma, biotech, devices)
- Study start
- 5 Oct 2022 (actual)
- Primary completion
- 16 Jan 2024 (actual)
- Study completion
- 16 Jan 2024 (actual)
- First posted
- 21 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and MERS-CoV. The trivalent vaccine candidate is designed to induce neutralizing antibody and cell-mediated immune responses against the spike protein of the original strain of SARS-CoV-2, SARS-CoV-2 variants (such as Beta, Delta and Omicron) and other related coronaviruses that could emerge in the future.
The Phase 1 study will be an open-label comparison of two intramuscular doses of VBI-2901a at 5 µg or 10 µg per dose or one dose of VBI-2901a at 10 µg per dose in adults 18 to 64 years of age who had previously received two or more vaccinations with licensed COVID-19 vaccines. The purpose of the study is to test the safety of VBI-2901a and to know more about its ability to boost immune response against SARS-CoV-2 (the virus that causes COVID-19 disease) and two other related coronaviruses SARS-CoV-1 and MERS-CoV.
Detailed description
VBI-2901a is an investigational trivalent COVID-19 vaccine candidate that comprises enveloped virus-like particles (eVLPs) expressing the spike proteins of the beta-coronaviruses SARS-CoV-2, SARS-CoV-1 and MERS-CoV. The study will enroll participants 18 to 64 years of age who have previously received two or more vaccinations with a licensed COVID-19 vaccine(s) and will test two intramuscular doses of VBI-2901a containing 5 µg or 10 µg of spike protein and one dose of VBI-2901a containing 10 µg of spike protein. VBI-2901a eVLPs are formulated with 0.33 mg of aluminum phosphate (alum) adjuvant per dose. VBI-2901a is designed to induce neutralizing antibody and cell-mediated immune responses against multiple coronavirus respiratory disease strains and variants of SARS-CoV-2.
This is a randomized, open-label Phase 1 study. The study will enroll adults, aged 18 to 64 years, who are healthy or in stable health; had previously received two or more vaccinations with a licensed COVID-19 vaccine(s) with the final dose administered a minimum of 6 months (24 weeks) prior to enrollment; have a negative PCR or rapid antigen SARS-CoV-2 test at screening; and have met all other eligibility criteria. Participants with a history of mild COVID-19 illness are eligible if they fully recovered a minimum of 6 months (24 weeks) prior to enrollment.
A total of 99 participants will be randomized at a 1:1:1 ratio to the following study groups:
Group G1: 33 participants to receive two doses of VBI-2901a at 5 µg per dose at Day 1 and Day 56.
Group G2: 33 participants to receive two doses of VBI-2901a at 10 µg per dose at Day 1 and Day 56.
Group G3: 33 participants to receive one dose of VBI-2901a at 10 µg per dose at Day 1.
The total study duration for each vaccinated subject is 48 weeks (336 days) after administration of the first dose of study vaccine. During the study, the participant will make 9 visits to the study site, including the screening visit.
The objective of the study is to select the optimal dose level (5 µg or 10 µg) and number of doses (1 or 2 doses) of trivalent coronavirus vaccine candidate VBI-2901a in individuals who had been vaccinated against COVID-19 previously. To achieve this objective, the study will evaluate outcomes including safety and tolerability as well as antibody and T cell immune responses against SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants, SARS-CoV-1 and MERS-CoV.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group G1 | Experimental | Biological: VBI-2901a33 participants aged 18-64 years to receive two doses of VBI-2901a at 5 µg per dose at Day 1 and Day 56. |
| Group G2 | Experimental | Biological: VBI-2901a33 participants aged 18-64 years to receive two doses of VBI-2901a at 10 µg per dose at Day 1 and Day 56. |
| Group G3 | Experimental | Biological: VBI-2901a33 participants aged 18-64 years to receive one dose of VBI-2901a at 10 µg per dose at Day 1. |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (15 listed)
- Male or female subject 18-64 years of age
- Be willing and able to provide personally signed informed consent indicating understanding of the purpose, procedures required for the study and potential risks and benefits of the study, and be willing to participate in the study
- Be healthy or in stable health. Participants with pre-existing, stable, well-controlled disease, defined as mild disease or medical condition not requiring medical therapy or not requiring a change in medical therapy due to worsening of disease during the 6 months before enrollment may be enrolled at the discretion of the investigator. Participants with history of asymptomatic SARS-CoV-2 infection who tested positive by PCR or rapid antigen test or participants with history of having signs and symptoms mild COVID-19 illness (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who did not have shortness of breath, dyspnea, or abnormal chest imaging are eligible for the study if they fully recovered a minimum of 6 months before enrollment.
- Meets reproductive inclusion criteria
- Female participant is eligible if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
Key exclusion criteria (26 listed)
- History of COVID-19 illness of moderate or greater severity, defined as one of the following:
- Participants with a known history of SARS-CoV-1 or MERS infection.
- Positive SARS-CoV-2 PCR or rapid antigen test at screening.
- Participant with a history of an underlying clinically significant acute or chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation in the study would not be in the best interest of the participant (e.g., could compromise participant's wellbeing) or that could prevent, limit, or confound the protocol-specified assessments.
- Individuals with medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VBI-2901aIntramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant. | Biological | Group G1, Group G2, Group G3 |
Primary outcome
Local reactions (solicited adverse events) within 7 days of study vaccination
Time frame: Through 7 days after each vaccination
Systemic reactions (solicited adverse events) within 7 days of study vaccination
Time frame: Through 7 days after each vaccination
Unsolicited adverse events within 28 days of study vaccination
Time frame: Through 28 days after each vaccination
Serious adverse events within 28 days of study vaccination and end of study
Time frame: Through end of study (approximately 1 year)
Medically-attended adverse events within 28 days of study vaccination and end of study
Time frame: Through end of study (approximately 1 year)
Seroresponse rate against SARS-CoV-2 ancestral (Wuhan) strain
Time frame: Study days 1, 28 and 84
Percent of participants with ≥ 4-fold rise in neutralizing antibody titer at 28 days after the first vaccination and, in participants receiving two doses, 28 days after the second vaccination, compared to baseline (Day 1).
7 secondary outcomes
Seroresponse rate against SARS-CoV-2 variants of concern (Beta, Delta and Omicron)
Time frame: Study days 1, 28 and 84
Seroresponse rate against SARS-CoV-1 and MERS-CoV
Time frame: Study days 1, 28 and 84
Geometric mean titer (GMT) of SARS-CoV-2 neutralizing antibodies
Time frame: Study days 1, 7, 28, 56, 63, 84, 168 and 336
Geometric mean fold rise (GMFR) in serum neutralizing antibody titer against SARS-CoV-2 ancestral (Wuhan) strain and variants of concern (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV
Time frame: Study days 1, 7, 28, 56, 63, 84, 168 and 336
GMT and GMFR in serum IgG antibody to spike protein and receptor-binding-domain (RBD) against SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV
Time frame: Study days 1, 7, 28, 56, 63, 84, 168, and 336
Interferon-gamma-positive cells against spike protein from SARS-CoV-2 ancestral (Wuhan) strain, selected SARS-CoV-2 variants (Beta, Delta and Omicron), SARS-CoV-1 and MERS-CoV
Time frame: Study days 1, 7, 28, 56, 63, and 84
Serum binding IgG subclasses
Time frame: Days 1, 7, 28, 56, 63, and 84
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2026.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William Cameron, MD principal investigator
Ottawa Hospital
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing VBI-2901a in people with COVID-19 and Coronavirus Infections, run by VBI Vaccines Inc. at 7 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Local reactions (solicited adverse events) within 7 days of study vaccination (time frame: Through 7 days after each vaccination). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.